2630 — Vigonvita Life Sciences Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$10.06bn
- HK$10.52bn
- KR₩12m
Annual cashflow statement for Vigonvita Life Sciences Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Net Income/Starting Line | 6.43 | -218 |
| Depreciation | ||
| Amortisation | ||
| Non-Cash Items | 24.1 | 33.4 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -16.7 | 41.7 |
| Change in Accounts Receivable | ||
| Change in Inventories | ||
| Change in Other Assets | ||
| Change in Payable / Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | 30.7 | -109 |
| Capital Expenditures | -159 | -88.1 |
| Purchase of Fixed Assets | ||
| Purchase / Acquisition of Intangibles | ||
| Other Investing Cash Flow Items | -1.66 | -0.265 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Other Investing Cash Flow | ||
| Cash from Investing Activities | -161 | -88.4 |
| Financing Cash Flow Items | -11.8 | -22.1 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 76.5 | 222 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -53.5 | 25.2 |